2004

• Name change to MIGENIX Inc.
• Health Canada CTA approval to initiate MBI-3253 Phase IIa study in HCV patients
• Acquisition of MitoKor Inc, acquisition to broaden therapeutic focus
• License agreement with Strata Pharmaceuticals Inc for development and commercialization of MBI-226
• $6.75 million equity financing completed
• Acquisition of MBI-3253 (celgosivir) for the treatment of chronic Hepatitis C Virus infections
• Meetings with FDA establishes regulatory path forward for MBI-226 and license agreement with Fujisawa terminated

2003

• Lead Development Candidate Identified (MBI-2401) in Lipopeptide Program for Serious Bacterial Infections
• Hepatitis B Compound licensed to Spring Bank Technologies - US$2.6 Million NIH Grant Funding Approved for Development
• Efficacy demonstrated from Phase IIb acne study - statistically significant data validates anti-acne properties of MBI 594AN
• Phase III trial results of MBI 226 - Statistical superiority not achieved in preventing catheter-related bloodstream infections
• Formation of Scientific Advisory Board
• Completion of full enrollment in pivotal Phase III trial of MBI 226
• Initiation of Phase IIb clinical trial of MBI 594AN for the treatment of acne

2002

• U.S. Based Biotechnology Value Fund, L.P. Invests $5.5 million in Micrologix
• Expansion and diversification of Company's pipeline through acquisition of antiviral product & technology portfolio - candidates targeted to Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), HIV and HCV Replication Assay
• Collaboration between Micrologix and Hybridon, Inc. of Cambridge, Massachusetts to develop antisense drug targeted to Human Papillomavirus (HPV)
• Completion of its planned senior management augmentation and restructuring - significant expertise from both biotech and pharmaceutical industries
• License agreement with Fujisawa Healthcare, Inc. for development & commercialization of MBI 226
• Acquisition of two preclinical, systemic anti-infective programs from IntraBiotics Pharmaceuticals, Inc. of Mountain View, California.
• Strategic Plan unveiled -  key action items for the 2003 fiscal year

2001

• Positive results from a Phase II trial of MBI 594AN for the treatment of acne.
• Appointment of Jim DeMesa, M.D. as the Company's new President and CEO.
• Completion of planned enrollment of 75 subjects for the Phase II clinical trial in the United States for MBI 594AN
• U.S. patents Nos. 6,180,604 and 6,191,254 granted, covering the compositions of 46 novel peptides and their chemical derivatives designed for unique activity against bacteria and fungi.

2000

• Added to TSE 300 Composite Index
• Initiated a Phase Ib clinical trial for MBI 853NL, a novel drug candidate for preventing hospital-acquired infections caused by Staphylococcus aureus (S. aureus), including methicillin-resistant S. aureus (MRSA).
• Initiated a Phase II clinical trial in the US of MBI 594AN for the treatment of acne.
• Initiated Phase III clinical trials in the United States for MBI 226.
• $8.6 million raised through the exercise of share purchase warrants and after-market support options.
• Completed a US Phase I human clinical trial of MBI 853NL, an antibiotic drug being developed for the prevention of hospital-acquired infections caused by Staphylococcus aureus (S. aureus).
• Completed a Phase I human clinical trial of MBI 594AN for the treatment of acne.
• Worldwide exclusive licensing and co-development agreement signed with the Harbor-UCLA Research and Education Institute (REI) of Torrance, California.
• $40 million special warrant equity financing completed.
• Initiated a Phase I clinical trial in the US of MBI 853NL, a potential new treatment to prevent hospital-acquired infections caused by Staphylococcus aureus (S. aureus), including methicillin-resistant S. aureus (MRSA).
• Initiated Phase I clinical trials in the US to evaluate the safety and antimicrobial activity of MBI 594AN in the treatment of acne.
• Successful completion of a two part US Phase II clinical trial as part of the fast track development program for MBI 226

1999

• Initiated U.S. Phase II clinical trial of MBI 226 for the prevention of catheter-related bloodstream infections.
• US Food and Drug Administration grants fast track designation to MBI 226
• $15 million special unit equity financing completed
• Successful completion of a two-part U.S. Phase I human clinical trial of MBI 226 for the prevention of bloodstream infections in patients undergoing central venous catheterization.
• Bactolysins offer significant potential to treat severe inflammatory acne, as shown by recent results from the Company's preclinical program. Micrologix plans to initiate clinical trials for the treatment of acne in the first quarter of 2000

1998

• Initiated U.S. Phase I human clinical trial of MBI 226 for the prevention of bloodstream infections in patients undergoing central venous catheterization
• Pre-IND package submitted to United States Food and Drug Administration (FDA) for first clinical indication
• In vitro effectiveness of four of the Company's Enhancin peptides in restoring the antibacterial activity of several antibiotics against clinical isolates of multidrug-resistant bacteria reported at the 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
• In vitro studies for ophthalmic pathogen susceptibility and in vivo ocular irritation studies show broad antimicrobial coverage, rapid killing and little or no irritation to the eye
• Expansion of Micrologix's leased office and laboratory facility
• In vitro studies demonstrate that Micrologix's peptides kill tumor cell lines responsible for several important human cancers
• Formation of Clinical Advisory Board
• Four-year agreement to co-develop novel antibiotics signed with the Protein Engineering Network of Centres of Excellence (PENCE)
• U.S. patents Nos. 5,707,855 and 5,688,767 issued, covering the composition of an antimicrobial compound under development and the use of this compound to kill bacteria, including claims to protect the use of this compound in combination with conventional antibiotics to enhance their activity

• In vitro studies demonstrate that an Enhancin compound under development by the Company restores the effectiveness of vancomycin against clinical isolates of vancomycin-resistant enterococcus (VRE); these results are presented at the 37th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
• Selection of a topical Bactolysin as the first lead compound, and commencement of preclinical studies required for the filing of an Investigational New Drug (IND) application in the United States (IND targeted to be filed in the second half of 1998)
• Licensing agreement signed with the University of Victoria's Innovation and Development Corporation for an enabling technology useful in the production of antimicrobial peptides
• $7.5 million raised through the exercise of share purchase warrants
• U.S. patent No. 5,593,866 issued for a recombinant DNA manufacturing technology under development by Micrologix

1996

• Early-stage animal studies demonstrate that several of the Company's novel compounds are effective in treating lethal systemic bacterial infections
• $5.75 million raised through the exercise of share purchase warrants
• In vitro results demonstrate the activity of Micrologix's innovative peptide antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE)
• Micrologix listed on the Toronto Stock Exchange

1995

• Establishment of corporate research facility and relocation of corporate offices
• $11 million special warrant equity financing completed
• Formation of Scientific Advisory Board
• Anti-cancer program initiated with the British Columbia Cancer Agency

1994

• $4.1 million equity private placement completed
• Agreement reached for divestiture of subsidiary companies engaged in developing and marketing healthcare and diagnostic products for the aquaculture industry.

1993

• Formation of Micrologix Biotech Inc. and listing on the Vancouver Stock Exchange
• Antimicrobial peptide technology licensed from the University of British Columbia
• Five-year, $500,000 research agreement initiated with the University of British Columbia